BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) announced that Kenneth L. Londoner, Chairman and CEO, will present at the 13th Annual LD Micro Main Event Conference on December 14, 2020, at 10:20 AM ET. The presentation will cover company highlights, showcasing the PURE EP™ System, which has been used in over 400 procedures by more than 25 electrophysiologists across six U.S. clinical sites. BioSig is focused on improving ECG and intra-cardiac signal fidelity through its proprietary biomedical signal processing platform.

Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the 13^th Annual LD Micro Main Event Conference on Monday, December 14, 2020 at 10:20 AM ET.

During the presentation, Mr. Londoner will provide an overview of the Company and business highlights. To date, more than 400 patient procedures have been conducted with the PURE EP™ System by more than 25 electrophysiologists across six different clinical sites in the United States.

To register for the conference, please click here:   

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

FAQ

When is Kenneth L. Londoner's presentation at the LD Micro Main Event Conference for BioSig Technologies (BSGM)?

Kenneth L. Londoner will present on December 14, 2020, at 10:20 AM ET.

What is the PURE EP™ System used for by BioSig Technologies (BSGM)?

The PURE EP™ System is designed for acquiring, digitizing, amplifying, and storing electrocardiographic and intracardiac signals during electrophysiology procedures.

How many patient procedures have been conducted with the PURE EP™ System?

Over 400 patient procedures have been performed with the PURE EP™ System.

How many electrophysiologists have used the PURE EP™ System?

More than 25 electrophysiologists have utilized the PURE EP™ System.

What is the purpose of BioSig Technologies' presentation at the conference?

The presentation aims to provide an overview of the company and highlight its recent business achievements.